Table 3.
Association of paliperidone palmitate v. other antipsychotic depots with clinical outcomes
| Follow-up period (n) | Number of inpatient days | Number of hospital admissions | ||
|---|---|---|---|---|
| Unadjusted B coefficient (95% confidence interval, p value) | aAdjusted B coefficient (95% confidence interval, p value) | Unadjusted incidence rate ratio (95% confidence interval, p value) | aAdjusted incidence rate ratio (95% confidence interval, p value) | |
| 12 months (n = 980) | 4.6 days (−7.6 to 16.8, p = 0.46) | −0.2 days (−12.3 to 11.9, p = 0.97) | 1.19 (0.90–1.57, p = 0.22) | 1.18 (0.88–1.58, p = 0.26) |
| 24 months (n = 623) | 1.5 days (−25.3 to 28.2, p = 0.92) | 0.82 days (−27.3 to 28.9, p = 0.95) | 1.14 (0.86–1.51, p = 0.36) | 1.00 (0.73–1.35, p = 0.98) |
| 36 months (n = 268) | 25.9 days (−41.9 to 93.7, p = 0.45) | 5.4 days (−57.3 to 68.2, p = 0.86) | 1.33 (0.80–2.19, p = 0.27) | 1.07 (0.62–1.83, p = 0.82) |
a
Adjusted for age, gender, ethnicity, marital status, diagnosis, borough of residence, whether started on LAI as an inpatient and number of hospital admissions in the 3 years prior to the index date.